COVID-19 cell therapy drives Mesoblast to seek manufacturing muscle 31-Aug-2020 By Nick Taylor Mesoblast plans “rapid scale-up in manufacturing” to meet anticipated demand for COVID-19 cell therapy.
AdComm backs Mesoblast cell therapy despite manufacturing concerns 18-Aug-2020 By Nick Taylor Advisory committee votes in favor of Mesoblast’s allogeneic cell therapy despite questions about manufacturing consistency.
Mesoblast and Lonza agree commercial manufacture of allogeneic cell therapy 22-Oct-2019 By Ben Hargreaves Lonza will manufacture mesoblast’s lead cell therapy ahead of a planned US market launch, which could occur next year.
Grünenthal sets down over $1bn for off-the-shelf cell therapy 12-Sep-2019 By Ben Hargreaves Grünenthal agrees deal with Mesoblast to develop and commercialize an allogeneic cell therapy for chronic lower back pain.